Abstract:
The liver is the only organ that neutralizes bilirubin, a toxic product of red blood cell
breakdown. The lack of preventive and therapeutic measures for the treatment of hepatitis of
various etiologies indicates the need to create new drugs that eliminate hyperbilirubinemia.
Asfervon has anti-inflammatory and prostate-protective effects. However, its effect on bilirubin
metabolism in acute toxic hepatitis has not been sufficiently studied. Various models of acute toxic
hepatitis (tetrachloromethane, heliotrin and drug) were reproduced on sexually mature male rats.
The exocrine function of the liver and the rate of bilirubin excretion in bile, as well as liver tests,
total bilirubin and its fractions in the blood serum were studied. It was found that in acute hepatitis
of various etiologies, there is a significant inhibition of the functional state of the liver accompanied
by a decrease in the exocrine function, a decrease in the concentration of bilirubin in the bile,
against the background of the development of cytolytic and cholestatic syndromes, hypoproteinemia
and hyperbilirubinemia. The latter is mainly due to an increase in the concentration of
unconjugated bilirubin, which indicates a decrease in the activity of the enzyme diphosphate
glucuronyl transferase. Experimental therapy with Asfervon eliminates the identified bilirubin
metabolism disorders. At the same time, it surpasses the well-known hepatoprotector, Karsil, in its
225
ҚАЗАҚСТАН МЕДИЦИНА ЖӘНЕ ФАРМАЦИЯ ЖУРНАЛЫ, 2024, 6-том
XI международная научная конференция молодых ученых и студентов «Перспективы
развития биологии, медицины и фармации», сборник статей
pharmacotherapeutic activity. Asfervon, which has low toxicity and high hypobilirubinemic activity,
can be recommended as an effective treatment for hepatitis of various etiologies.
